论文部分内容阅读
目的观察诺和龙与阿托伐他汀联合用药对更年期女性糖尿病肾病(DN)患者蛋白尿的治疗效果。方法将更年期女性DN患者100例随机分为单纯诺和龙治疗组(对照组)和诺和龙联合阿托伐他汀治疗组(观察组)各50例,对照组给予诺和龙,观察组除给予诺和龙外还每日口服阿托伐他汀1次,两组患者均接受常规的饮食运动治疗,疗程3个月。检测治疗前、后两组DN患者的血总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、24 h尿蛋白排泄率(UAER)、24h尿蛋白定量(UPr)、肾小球滤过率(GFR)。结果治疗后两组更年期女性DN患者的TC、TG、LDL-C、UAER、UPr均较治疗前明显降低,差异有统计学意义(P<0.05),且观察组较对照组降低明显,差异有统计学意义(P<0.05);GFR在两组治疗前、后差异无统计学意义(P>0.05)。结论诺和龙与阿托伐他汀联合治疗能更为有效的降低更年期女性DN患者血脂和减少蛋白尿,从而延缓肾功能衰竭发挥保护肾脏的作用。
Objective To observe the therapeutic effect of combination of noradrenon and atorvastatin on proteinuria in climacteric women with diabetic nephropathy (DN). Methods One hundred cases of menopausal women with DN were randomly divided into three groups: noradrenaline group (control group) and noradrenon combined with atorvastatin group (n = 50), and control group (n = Dayton and Norovirus were also given a daily oral atorvastatin 1 times, two groups of patients were given conventional diet exercise treatment for 3 months. Blood TC, TG, LDL-C, UAER and 24-hour urinary protein were measured before and after treatment in both groups UPr), glomerular filtration rate (GFR). Results After treatment, TC, TG, LDL-C, UAER and UPr of menopausal women with DN in the two groups were significantly lower than those before treatment (P <0.05), and the observation group was significantly lower than the control group Statistical significance (P <0.05); There was no significant difference in GFR between the two groups before and after treatment (P> 0.05). Conclusion Combination therapy with norvoralon and atorvastatin can effectively reduce the blood lipids and proteinuria in menopausal women with DN and delay the renal failure to protect the kidneys.